Patent ID: 8778390

Claim:
A methylphenidate aqueous extended release oral suspension comprising an immediate release methylphenidate component, a sustained release methylphenidate component, and water, wherein said suspension is stable at room temperature for at least one month and provides a single mean average plasma concentration peak and a therapeutically effective plasma profile for about 12 hours for methylphenidate, and wherein the suspension has a pharmacokinetic profile in which the single mean plasma concentration peak for methylphenidate has an area under the curve (AUC) 0-∞ of about 114 ng-hr/mL to about 180 ng-hr/mL, C max of about 11 ng/mL to about 17 ng/mL, T max of about 4 hours to about 5.25 hours and T 1/2 of about 5 hours to about 7 hours following a single oral administration of an aqueous liquid suspension at a dose equivalent to 60 mg racemic methylphenidate HCl in adults.